MicroVention Announces 5-Year Clinical Trial Data and Size Additions for its WEB Aneurysm Embolization System; WEB is Most Well-Studied Intrasaccular Device Available Today

July 31, 2023

Corporate

ALISO VIEJO, Calif. – July 31, 2023 – MicroVention, Inc. today announced new 5-year clinical trial data along with size additions for its WEB™ Aneurysm Embolization System, reinforcing WEB's position as the most well-studied intrasaccular device available today.

The 5-year data demonstrate durable, long-term aneurysm occlusion outcomes and continued favorable safety results, adding to the extensive body of clinical evidence supporting the WEB System across a broad range of aneurysm types and sizes.

Alongside the new data, MicroVention announced additional size options for the WEB System, expanding the range of aneurysm anatomies that can be treated with this intrasaccular flow disruption technology.

"With over a decade of clinical use and now five years of long-term data, WEB continues to demonstrate durable outcomes for patients with complex aneurysms," said a MicroVention representative. "These new size additions further expand our ability to treat a broader range of patients."

About MicroVention

MicroVention, Inc. is committed to advancing the treatment of complex diseases within the neurovascular market by providing innovative technologies and evidence-driven education for physicians dedicated to improving patient care. As a wholly owned subsidiary of Terumo Corporation, MicroVention develops, manufactures and markets innovative neuro-interventional products and services for the diagnosis and treatment of neurovascular diseases and adjacent markets.

About Terumo India

Terumo India is a fast-growing medical devices company that serves to advance access to high-quality Cardiac & Vascular, and other medical devices for patients and medical practitioners in India. Terumo India is part of Terumo Corporation, a global leader in medical technology with headquarters in Tokyo, Japan. Established in 1921 and with its 100 years of history, Terumo's starting point and unchanging corporate mission has been 'Contributing to Society through Healthcare'.

Terumo India was established in 2013 with headquarters in Gurgaon, NCR Delhi and has since grown to touch over 100,000 lives with an expanding field force & distribution network. Terumo India is Great Place to Work® certified and has also been recognized as one of India's Top 15 Workplaces™ in Pharmaceuticals, Healthcare and Biotech 2022. The company runs several acclaimed training & development programs, working closely with its customers and academic partners to contribute to the skilling requirements of India's healthcare system.

Media Contact

Terumo India Private Limited

About Terumo

Terumo (TSE: 4543) is a global medical innovation company. Guided by an unwavering commitment to patients, and driven by the passion of our associates, we strive to fulfill our Group Mission of "Contributing to Society through Healthcare." Founded in Tokyo in 1921, we provide a comprehensive range of solutions in the fields of therapeutic procedures, hospital operations, and life sciences in more than 160 countries and regions.

Media Contact

Corporate Communication Dept., Terumo Corporation

Among the information that Terumo discloses, the forward-looking statements including financial projections are based upon our assumptions using information available to us at the time and are not intended to be guarantees of future events or performance. Accordingly, it should be noted that actual results may differ from those forecasts or projections due to various factors. Factors affecting to actual results include, but are not limited to, changes in economic conditions surrounding Terumo, fluctuations of foreign exchange rates, and state of competition.

Information about products (including products currently in development) included in this material is not intended to constitute an advertisement or medical advice.